Paul M Sondel

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
    Kaci L Osenga
    The University of Wisconsin Madison, Madison, Wisconsin, USA
    Clin Cancer Res 12:1750-9. 2006
  2. pmc Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease
    Paul M Sondel
    Department of Pediatrics, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    J Clin Invest 112:25-7. 2003
  3. ncbi request reprint Preclinical and clinical development of immunocytokines
    Paul M Sondel
    Department of Pediatrics, Human Oncology, Genetics and Medicine and the University of Wisconsin Comprehensive Cancer Center, The University of Wisconsin Madison, 600 Highland Avenue, Madison, WI 53792, USA
    Curr Opin Investig Drugs 4:696-700. 2003
  4. ncbi request reprint In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages
    Hillary D Lum
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    J Leukoc Biol 79:1181-92. 2006
  5. pmc Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides
    Ilia N Buhtoiarov
    Department of Human Oncology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53792 4672, USA
    Immunology 120:412-23. 2007
  6. pmc Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects
    Alexander L Rakhmilevich
    Department of Human Oncology, University of Wisconsin, 4136 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA
    Cancer Immunol Immunother 61:1683-97. 2012
  7. pmc Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy
    Brenda L Soto
    Department of Human Oncology, University of Wisconsin, Madison, WI 53706, USA
    Int Immunopharmacol 11:1877-86. 2011
  8. pmc Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha
    Hillary D Lum
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    Immunology 118:261-70. 2006
  9. doi request reprint CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors
    Alexander L Rakhmilevich
    The Department of Human Oncology, University of Wisconsin, K4 413 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Immunol Immunother 57:1151-60. 2008
  10. pmc Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention
    Richard K Yang
    Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA
    J Immunol 189:2656-64. 2012

Collaborators

Detail Information

Publications44

  1. pmc A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
    Kaci L Osenga
    The University of Wisconsin Madison, Madison, Wisconsin, USA
    Clin Cancer Res 12:1750-9. 2006
    ..Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors...
  2. pmc Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease
    Paul M Sondel
    Department of Pediatrics, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    J Clin Invest 112:25-7. 2003
  3. ncbi request reprint Preclinical and clinical development of immunocytokines
    Paul M Sondel
    Department of Pediatrics, Human Oncology, Genetics and Medicine and the University of Wisconsin Comprehensive Cancer Center, The University of Wisconsin Madison, 600 Highland Avenue, Madison, WI 53792, USA
    Curr Opin Investig Drugs 4:696-700. 2003
    ..Clinical testing of ICs has recently begun using an anti-GD2 monoclonal antibody linked to interleukin-2 (IL-2) (hu14.18-IL-2), and using an antibody directed against the human epithelial cell adhesion molecule linked to IL-2 (KS-IL-2)...
  4. ncbi request reprint In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages
    Hillary D Lum
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    J Leukoc Biol 79:1181-92. 2006
    ..Taken together, our results show that anti-CD40 mAb immunotherapy of mice can inhibit tumor growth in the absence of T cells, NK cells, and PMN through the involvement of activated Mphi...
  5. pmc Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides
    Ilia N Buhtoiarov
    Department of Human Oncology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53792 4672, USA
    Immunology 120:412-23. 2007
    ..Taken together, our results indicate that the growth control of weakly immunogenic tumours during CpG-immunotherapy is mediated predominantly by Mphi, rather than T cells or NK cells...
  6. pmc Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects
    Alexander L Rakhmilevich
    Department of Human Oncology, University of Wisconsin, 4136 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA
    Cancer Immunol Immunother 61:1683-97. 2012
    ..Inhibition of NO did not abrogate the antitumor effects of stimulated myeloid cells. Taken together, the results indicate that in tumor-bearing hosts, tumor-associated myeloid cells can be activated to mediate antitumor effects...
  7. pmc Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy
    Brenda L Soto
    Department of Human Oncology, University of Wisconsin, Madison, WI 53706, USA
    Int Immunopharmacol 11:1877-86. 2011
    ..Results showed that this RV regimen inhibited the growth of NXS2 tumors in vivo but did not appear to interfere with blood cell count, splenocyte or macrophage function. Thus, RV may be a candidate for combining with immunotherapy...
  8. pmc Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha
    Hillary D Lum
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    Immunology 118:261-70. 2006
    ..Taken together, these results suggest that NO and TNF-alpha are involved in, but not solely responsible for, the antitumour effects of macrophages after activation by CD40 ligation...
  9. doi request reprint CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors
    Alexander L Rakhmilevich
    The Department of Human Oncology, University of Wisconsin, K4 413 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Immunol Immunother 57:1151-60. 2008
    ..Taken together, our results indicate that antitumor effects induced by alphaCD40, even against immunogenic tumors, can be observed in the absence of T cells and may involve macrophages...
  10. pmc Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention
    Richard K Yang
    Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA
    J Immunol 189:2656-64. 2012
    ..v.-IC. Overall, IT-IC resulted in increased numbers of activated T and NK cells within tumors, better IC retention in the tumor, enhanced inhibition of tumor growth, and improved survival compared with i.v.-IC...
  11. pmc Intratumoral immunocytokine treatment results in enhanced antitumor effects
    Erik E Johnson
    Department of Surgery, University of Wisconsin, Madison, WI, 53792, USA
    Cancer Immunol Immunother 57:1891-902. 2008
    ..Further testing is required to determine how to potentially incorporate IT administration of IC into an antitumor regimen that optimizes local and systemic anticancer therapy...
  12. ncbi request reprint Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy
    Zane C Neal
    Department of Human Oncology, University of Wisconsin Madison, Madison, Wisconsin 53792, USA
    Clin Cancer Res 10:4839-47. 2004
    ..Animals showing prolonged tumor eradication of established tumors after the combined hu14.18-IL2 plus IL-2 regimen exhibited a protective T-cell-dependent antitumor memory response against NXS2 rechallenge...
  13. pmc Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma
    Jacquelyn A Hank
    The University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 15:5923-30. 2009
    ..18) and interleukin (IL)-2. Sixty-one melanoma and neuroblastoma patients received IC in phase I/Ib studies. Patient sera were examined in ELISA to determine if an anti-IC antibody response occurred during treatment...
  14. pmc Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia
    Qing Li Wu
    Department of Pathology and Laboratory Medicine, Pediatrics University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Immunol 182:6771-8. 2009
    ..Our results suggest a novel immunotherapeutic strategy for CLL that may be effective even in the face of tumor or chemotherapy-induced T cell immunodeficiency...
  15. ncbi request reprint Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory
    Zane C Neal
    Mirus Bio Corporation, Madison, WI 53719, USA
    Cancer Immunol Immunother 56:1765-74. 2007
    ..Mice that received combined FL gene therapy plus IC exhibited complete and durable resolution of established NXS2 tumors, and demonstrated protection from subsequent rechallenge with NXS2 tumor...
  16. pmc Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
    Mark R Albertini
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Cancer Immunol Immunother 61:2261-71. 2012
    ..We conclude that subsequent testing of hu14.18-IL2 should involve melanoma patients with minimal residual disease based on compelling preclinical data and the confirmed immune activation with some antitumor activity in this study...
  17. pmc Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules
    Ilia N Buhtoiarov
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    J Immunol 182:1940-53. 2009
    ..These results suggest that contact with certain tumor cells via CD40, NKG2D, and CD18 molecules on the Mphi may facilitate Mphi-mediated antitumor immune surveillance...
  18. doi request reprint Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface
    Jennifer A A Gubbels
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI 53711, USA
    Cancer Immunol Immunother 60:1789-800. 2011
    ..These findings demonstrate that the IL-2 component of the IC allows IL2Rs to function not only as receptors for this cytokine but also as facilitators of peritoneal NK cell binding to IC-coated tumor cells...
  19. pmc Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma
    Erik E Johnson
    Departments of Surgery, Human Oncology, and Pediatrics and Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792, USA
    Clin Cancer Res 15:4875-84. 2009
    ..Radiofrequency ablation (RFA) is a common treatment modality for surgically unresectable tumors. However, there is a high rate of both local and systemic recurrence...
  20. pmc Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival
    Richard K Yang
    The Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA
    Cancer Immunol Immunother 62:1303-13. 2013
    ..18-IL2 treatment is necessary for long-term survival. This model demonstrates that tumor size is a strong predictor of hu14.18-IL2-induced lymphocyte infiltration and treatment outcome...
  21. pmc Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting
    Ilia N Buhtoiarov
    UW Carbone Cancer Center, 4159 MACC Fund UW Childhood Cancer Research Wing, WIMR, 1111 Highland Ave, Madison, WI 53705 2275, USA
    J Leukoc Biol 89:625-38. 2011
    ..These studies demonstrate that once IC binds to the tumor, it is present on the tumor surface for a prolonged time, inducing the recruitment of NK cells to the tumor site, followed by tumor cell killing...
  22. pmc Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
    Ilia N Buhtoiarov
    Department of Human Oncology, University of Wisconsin, Madison, WI 53705 2275, USA
    Immunology 132:226-39. 2011
    ..Together, the results show that CT and anti-CD40 + CpG-ODN IT synergize in the induction of anti-tumour effects which are associated with the phenotypic repolarization of tumour-associated Mφ...
  23. ncbi request reprint Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects
    Ilia N Buhtoiarov
    Department of Human Oncology and Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792, USA
    J Immunol 176:309-18. 2006
    ....
  24. ncbi request reprint Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
    Brian S Choi
    Department of Medicine, University of Wisconsin, Madison, 53792, USA
    Cancer Immunol Immunother 55:761-74. 2006
    ..We conducted a phase I trial of interleukin 2 (IL-2) in combination with chimeric 14.18 (ch14.18) and murine R24 antibodies to determine the maximal tolerated dose (MTD), immunological effects, and toxicity of this treatment combination...
  25. pmc Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice
    Erik E Johnson
    Paul P Carbone Comprehensive Cancer Center, Department of Surgery, University of Wisconsin, Madison, WI, USA
    J Immunother 34:76-84. 2011
    ..These results suggest that therapeutic strategies to activate macrophages may have potential for clinical application in cancer patients receiving chemotherapy...
  26. pmc The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model
    Brenda L Soto
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    Cancer Immunol Immunother 60:731-8. 2011
    ..These results demonstrate that the combination therapy of peritumoral resveratrol plus intravenous immunocytokine provides better anti-tumor effects in this model than either therapy alone...
  27. pmc Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG
    Kory L Alderson
    Department of Human Oncology, University of Wisconsin Madison, Madison, WI, USA
    Cancer Immunol Immunother 62:665-75. 2013
    ....
  28. pmc The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
    Brett H Yamane
    The University of Wisconsin Madison, Departments of Surgery, WI 53792, USA
    Expert Opin Investig Drugs 18:991-1000. 2009
    ..Preclinical and initial clinical data suggest greater efficacy in the setting of minimal residual disease; therefore, future clinical testing is planned to test the benefit of EMD-273063 in this setting...
  29. ncbi request reprint CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro
    Ilia N Buhtoiarov
    Department of Human Oncology and UW Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792, USA
    J Immunol 174:6013-22. 2005
    ..IFN-gamma production by macrophages was dependent on IL-12. Taken together, the results show that murine macrophages are activated directly by anti-CD40 mAb to secrete IFN-gamma and mediate tumor cell destruction...
  30. pmc Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy
    David C Delgado
    Department of Pediatrics, University of Wisconsin, Madison, Wisconsin, USA
    Cancer Res 70:9554-61. 2010
    ..These analyses indicate that response or improvement of relapsed/refractory NBL patients after IC treatment is associated with autologous KIR/KIR-ligand mismatch, consistent with a role for natural killer cells in this clinical response...
  31. ncbi request reprint Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma
    Mark R Albertini
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Cancer Chemother Biol Response Modif 22:789-97. 2005
  32. ncbi request reprint A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients
    Ryan D Cassaday
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Clin Cancer Res 13:540-9. 2007
    ..The aims of this phase I study were to assess the safety and immunologic effects of PMED of these genes in melanoma patients...
  33. pmc T-cell-independent antitumor effects of CD40 ligation
    Alexander L Rakhmilevich
    Department of Human Oncology and Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Madison, Madison, WI 53705, USA
    Int Rev Immunol 31:267-78. 2012
    ..In this review the authors focus on the ability of CD40 ligation to activate antitumor effector mechanisms of the cells of innate immunity such as macrophages and NK cells...
  34. ncbi request reprint Antibody-based immunotherapy in high-risk neuroblastoma
    Erik Johnson
    Department of Surgery, The University of Wisconsin Madison, WI 53792, USA
    Expert Rev Mol Med 9:1-21. 2007
    ..Future therapies under investigation in the area of immunotherapy for neuroblastoma are considered...
  35. pmc Immunotherapy for pediatric cancer
    Stephan A Grupp
    Division of Oncology, Department of Pediatrics, Department of Pathology and Laboratory Medicine, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Biol Blood Marrow Transplant 14:33-43. 2008
    ..This review explores how 3 components of the immune system--T cells, natural killer (NK) cells, and antibodies--can be used for therapy of pediatric malignancies...
  36. ncbi request reprint Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model
    Fushun Shi
    Department of Surgery, University of Wisconsin Madison, Madison, Wisconsin 53792, USA
    Mol Cancer Ther 1:949-57. 2002
    ..These results indicate that direct intratumoral gene transfer with naked nonviral IL-12 DNA provides an effective and simple method for the treatment of murine tumors, suggesting an approach for clinical application...
  37. doi request reprint Suppression of T-cell expansion by melanoma is exerted on resting cells
    Andrew J Russ
    Section of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Ann Surg Oncol 18:3848-57. 2011
    ..Immunotherapeutic cancer protocols often rely on the ability to promote proliferative expansion of tumor-specific T-cell, but the influence of cancer on in vivo T-cell expansion remains largely undefined...
  38. ncbi request reprint Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody
    Alexander L Rakhmilevich
    K4 413 Clinical Science Center, Department of Human Oncology, University of Wisconsin Madison, 600 Highland Avenue, Madison, WI 53792, USA
    Mol Cancer Ther 3:969-76. 2004
    ..Our results show a therapeutic benefit of combining IL-12 gene therapy and anti-VEGFR-2 mAb for cancer treatment...
  39. pmc Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity
    Kory L Alderson
    Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA
    J Biomed Biotechnol 2011:379123. 2011
    ..Therefore more research is needed that focuses on evaluating which NK cell and tumor criteria are best predictive of a clinical response and which combination immunotherapy regimens to pursue for distinct clinical settings...
  40. ncbi request reprint NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy
    Zane C Neal
    University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Madison, 600 Highland Ave, K4 448, Madison, WI 53792, USA
    Cancer Immunol Immunother 53:41-52. 2004
    ....
  41. ncbi request reprint Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine
    Jacquelyn A Hank
    Comprehensive Cancer Center, Department of Human Oncology, University of Wisconsin, Madison, WI, USA
    Methods Mol Med 85:123-31. 2003
  42. ncbi request reprint Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study
    Michael Imboden
    Department of Human Oncology, University of Wisconsin Madison, Madison, WI 53792, USA
    Hum Gene Ther 14:1037-48. 2003
    ....
  43. pmc Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group
    Judith G Villablanca
    Children s Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA
    Clin Cancer Res 17:6858-66. 2011
    ..To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma...
  44. pmc Up-regulation of Fas (CD95) expression in tumour cells in vivo
    Naama Peshes-Yaloz
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Immunology 120:502-11. 2007
    ..Our model is that host lymphoid cells in response to a tumour increase NO synthesis, which in turn causes enhanced Fas expression in the tumour...